Join
Live feed
·
PRReleasevia Quantisnow
AbbVie Inc. logo

UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment

ByQuantisnow·Wall Street's wire, on your screen.
ABBV· AbbVie Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABBV (AbbVie Inc.) and more on Quantisnow.